JP2018531218A5 - - Google Patents

Download PDF

Info

Publication number
JP2018531218A5
JP2018531218A5 JP2018507641A JP2018507641A JP2018531218A5 JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5 JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018507641 A JP2018507641 A JP 2018507641A JP 2018531218 A5 JP2018531218 A5 JP 2018531218A5
Authority
JP
Japan
Prior art keywords
group
tautomer
pharmaceutically acceptable
acceptable salt
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018507641A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531218A (ja
JP2018531218A6 (ja
JP6898306B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2016/092989 external-priority patent/WO2017024968A1/zh
Publication of JP2018531218A publication Critical patent/JP2018531218A/ja
Publication of JP2018531218A6 publication Critical patent/JP2018531218A6/ja
Publication of JP2018531218A5 publication Critical patent/JP2018531218A5/ja
Application granted granted Critical
Publication of JP6898306B2 publication Critical patent/JP6898306B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018507641A 2015-08-07 2016-08-03 Fgfr及びvegfr阻害剤であるビニル化合物 Active JP6898306B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201510484124 2015-08-07
CN201510484124.6 2015-08-07
CN201510908082 2015-12-09
CN201510908082.4 2015-12-09
PCT/CN2016/092989 WO2017024968A1 (zh) 2015-08-07 2016-08-03 作为fgfr和vegfr抑制剂的乙烯基化合物

Publications (4)

Publication Number Publication Date
JP2018531218A JP2018531218A (ja) 2018-10-25
JP2018531218A6 JP2018531218A6 (ja) 2018-12-13
JP2018531218A5 true JP2018531218A5 (cg-RX-API-DMAC7.html) 2019-09-19
JP6898306B2 JP6898306B2 (ja) 2021-07-07

Family

ID=57983012

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018507641A Active JP6898306B2 (ja) 2015-08-07 2016-08-03 Fgfr及びvegfr阻害剤であるビニル化合物

Country Status (5)

Country Link
US (1) US10519133B2 (cg-RX-API-DMAC7.html)
EP (1) EP3333157B1 (cg-RX-API-DMAC7.html)
JP (1) JP6898306B2 (cg-RX-API-DMAC7.html)
CN (1) CN107922349B (cg-RX-API-DMAC7.html)
WO (1) WO2017024968A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3584241B1 (en) * 2017-02-14 2023-04-26 FUJIFILM Corporation Method for producing indazole compound, and indazole compound
JP6974618B2 (ja) * 2017-12-07 2021-12-01 ハルビン チェンバオ ファーマシューティカル カンパニー リミテッド Fgfr及びvegfr阻害剤としての化合物の塩形態、結晶形およびその製造方法
CN113490667B (zh) * 2018-12-29 2023-10-27 盛世泰科生物医药技术(苏州)股份有限公司 作为fgfr和vegfr双重抑制剂的咪唑并吡啶衍生物
CA3128282C (en) * 2019-02-02 2024-10-15 Novaonco Js Therapeutics Co., Ltd. VINYLBENZAMIDE COMPOUNDS AS PD-L1 IMMUNOMODULATORS
US12152013B2 (en) 2019-02-02 2024-11-26 Novaonco Js Therapeutics Co., Ltd. Vinylpyridine carboxamide compound as PD-L1 immunomodulator
AU2020292664B2 (en) * 2019-06-14 2023-04-13 Cgenetech (Suzhou, China) Co., Ltd. Fused ring compound as FGFR and VEGFR dual inhibitor
WO2021088859A1 (zh) * 2019-11-06 2021-05-14 暨南大学 吲唑类化合物及其药用组合物和应用
WO2021138391A1 (en) * 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
EP4186894B1 (en) * 2020-08-11 2024-12-04 Henan Medinno Pharmaceutical Technology Co., Ltd. Fgfr inhibitor compound and use thereof
EP4262796A4 (en) * 2020-12-17 2025-04-02 Blossomhill Therapeutics, Inc. MACROCYCLES AND THEIR USE
CN116761798A (zh) * 2020-12-30 2023-09-15 泰拉生物科学公司 作为激酶抑制剂的吲唑类化合物
CR20230325A (es) 2020-12-30 2023-12-11 Tyra Biosciences Inc Compuestos de indazol como inhibidores de cinasas
WO2023279041A1 (en) * 2021-06-30 2023-01-05 Tyra Biosciences, Inc. Indazole compounds
KR20250040643A (ko) * 2022-06-29 2025-03-24 타이라 바이오사이언시스, 인크. 인다졸 화합물
CN116239623B (zh) * 2022-11-18 2025-11-18 江西亚太科技发展有限公司 一种硼酸酯的制备方法及其应用
WO2024137742A1 (en) 2022-12-20 2024-06-27 Blueprint Medicines Corporation Compounds and compositions as fgfr3 degraders and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020010137A1 (en) * 1997-09-18 2002-01-24 Genentech, Inc. Methods and compositions for inhibiting neoplastic cell growth
YU54202A (sh) * 2000-01-18 2006-01-16 Agouron Pharmaceuticals Inc. Jedinjenja indazola, farmaceutske smeše i postupci za stimulisanje i inhibiranje ćelijske proliferacije
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
DE60132937T2 (de) 2000-09-11 2009-02-12 Novartis Vaccines and Diagnostics, Inc., Emeryville Verfahren zur Herstellung von Benzimidazol-2-yl -Chinolinonderivaten
EP1401831A1 (en) * 2001-07-03 2004-03-31 Chiron Corporation Indazole benzimidazole compounds as tyrosine and serine/threonine kinase inhibitors
KR20050004214A (ko) 2002-05-31 2005-01-12 에자이 가부시키가이샤 피라졸 화합물 및 이것을 포함하여 이루어지는 의약 조성물
CA2508319A1 (en) * 2002-12-03 2004-06-17 Kyowa Hakko Kogyo Co., Ltd. Jnk inhibitors
EA008501B1 (ru) * 2002-12-19 2007-06-29 Пфайзер Инк. 2-(1н-индазол-6-иламино)бензамидные соединения как ингибиторы протеинкиназ, полезные для лечения офтальмологических заболеваний
WO2007058626A1 (en) * 2005-11-16 2007-05-24 S*Bio Pte Ltd Indazole compounds
MX2008012482A (es) * 2006-03-31 2008-10-10 Abbott Lab Compuestos de indazol.
AR078411A1 (es) * 2009-05-07 2011-11-09 Lilly Co Eli Compuesto de vinil imidazolilo y composicion farmaceutica que lo comprende

Similar Documents

Publication Publication Date Title
JP2018531218A5 (cg-RX-API-DMAC7.html)
KR102820455B1 (ko) Shp2 활성 억제용 화합물의 제조 방법
JP2019524883A5 (cg-RX-API-DMAC7.html)
JP2020169171A5 (cg-RX-API-DMAC7.html)
JP2006515858A5 (cg-RX-API-DMAC7.html)
JP2017504576A5 (cg-RX-API-DMAC7.html)
JP2016121196A5 (cg-RX-API-DMAC7.html)
JP2018528261A5 (cg-RX-API-DMAC7.html)
JP2016515560A5 (cg-RX-API-DMAC7.html)
JP2020510091A5 (cg-RX-API-DMAC7.html)
JP2014503525A5 (cg-RX-API-DMAC7.html)
JP2020529994A5 (cg-RX-API-DMAC7.html)
JP2016504387A5 (cg-RX-API-DMAC7.html)
JP2017507160A5 (cg-RX-API-DMAC7.html)
JP2016130266A5 (cg-RX-API-DMAC7.html)
JP2008505157A5 (cg-RX-API-DMAC7.html)
JP2020063289A5 (cg-RX-API-DMAC7.html)
JP2020500869A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
JP2015511232A5 (cg-RX-API-DMAC7.html)
JP2020128426A5 (cg-RX-API-DMAC7.html)
CN112771045A (zh) 喹啉并吡咯烷-2-酮类衍生物及其应用
JP2006509842A5 (cg-RX-API-DMAC7.html)
RU2016151420A (ru) Новое терапевтическое применение производных бензилиденгуанидина для лечения протеинопатий
JP2017519796A5 (cg-RX-API-DMAC7.html)